More forecasts: Atlanta 30 day forecast
Redwood City Biotech Scores As Neurocrine Drops $2.9 Billion On Prader‑Willi Drug
Apr 06, 2026
Neurocrine will pay $53 a share to buy Redwood City’s Soleno for about $2.9B, adding VYKAT XR — the first FDA‑approved treatment for hyperphagia in Prader‑Willi syndrome.












